GO:0004305 ethanolamine kinase activity explained

Ethanolamine kinase activity (GO:0004305) is a molecular function defined as the catalysis of the reaction ATP + ethanolamine = ADP + 2 H+ + phosphoethanolamine. This phosphorylation event is the first committed step in the CDP-ethanolamine pathway, the route by which cells generate phosphatidylethanolamine (PE), a major membrane phospholipid. Because the reaction converts a free, water-soluble base into a charged intermediate that can be further activated and coupled to diacylglycerol, it occupies a strategic position at the entry point of PE biosynthesis. Researchers study this activity to understand how cells allocate headgroup precursors between choline and ethanolamine arms of phospholipid metabolism, and how that allocation is adjusted by diet, tissue type, and developmental state. The enzyme or enzymes responsible for ethanolamine kinase activity have been characterized biochemically in several mammalian tissues. Early fractionation work established that choline kinase and ethanolamine kinase behave as separate, soluble enzymes in rat liver, arguing against a single broad-specificity kinase accounting for both activities. In nervous tissue, ethanolamine kinase activity has been detected in purified myelin and in the cytosol of nerve endings from rat forebrain, consistent with a role in maintaining the phospholipid environment of neuronal membranes. Dietary manipulation also influences the activity: in choline-deficient rats, hepatic ethanolamine kinase activity and the compositions of diacylglycerols, phosphatidylcholines, and phosphatidylethanolamines are altered, indicating that this step is sensitive to nutritional input. Functionally, the importance of ethanolamine kinase activity extends beyond housekeeping lipid synthesis. Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway, showing that the enzyme can exert control over metabolic flux. Downstream PE produced through this route participates in signaling and immune regulation, including control of T follicular helper cells and humoral immunity. In humans, defects in choline/ethanolamine kinase biology are associated with CHKB-related muscular dystrophy, a disorder that underscores the clinical relevance of this metabolic node. This article summarizes the definition, mechanism, genes, regulation, disease links, and experimental methods relevant to GO:0004305, with all factual statements tied to the verified literature.

In practical terms, ethanolamine kinase activity is the enzyme function that takes ethanolamine, a small nitrogen-containing alcohol, and attaches a phosphate group to it using ATP as the phosphate donor. The reaction consumes one molecule of ATP and one molecule of ethanolamine and produces ADP, two protons, and phosphoethanolamine. This is a transferase-type phosphorylation reaction, and it is the first step that commits ethanolamine to the CDP-ethanolamine pathway for phosphatidylethanolamine biosynthesis. The activity is defined by its substrate specificity for ethanolamine and by its dependence on ATP, and it is distinct from choline kinase activity, which phosphorylates the related alcohol choline.

Ethanolamine kinase activity matters because it gates the supply of phosphoethanolamine for phosphatidylethanolamine synthesis, and phosphatidylethanolamine is not only a bulk membrane lipid but also a precursor and regulator in multiple cellular processes. Because the reaction is the first committed step of the CDP-ethanolamine pathway, changes in its level or regulation can shift the balance between phosphatidylcholine and phosphatidylethanolamine, alter membrane composition, and influence downstream signaling. The activity is also relevant to neurobiology, since it is present in myelin and nerve endings where membrane lipid turnover is intense, and to immunology, because phosphatidylethanolamine metabolism controls T follicular helper cells and humoral immunity. Clinically, disturbances in ethanolamine/choline kinase biology are linked to CHKB-related muscular dystrophy, and hyperhomocysteinemia-associated glomerular injury involves lipid peroxidation and ferroptosis pathways in which phospholipid metabolism is implicated. For these reasons, ethanolamine kinase activity is a meaningful node for metabolic, neurological, immunological, and disease-oriented research.

The following genes and proteins are directly or contextually associated with ethanolamine kinase activity, its pathway, or its downstream phospholipid products in the verified literature.

Ethanolamine kinase activity is regulated at multiple levels according to the available literature. Nutritionally, hepatic ethanolamine kinase activity and the composition of diacylglycerols, phosphatidylcholines, and phosphatidylethanolamines change in choline-deficient rats, indicating that dietary choline status modulates this step. At the pathway level, overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway, showing that the amount of enzyme can influence metabolic flux. Tissue-specific regulation is also evident from the distinct distribution of the activity in liver versus nervous tissue fractions, where it appears in soluble and myelin-associated compartments. Downstream, phosphatidylethanolamine levels influence T follicular helper cell and humoral immune programs, providing a physiological context in which pathway output is coupled to cell state. In disease settings, oxidative and ferroptosis-related pathways intersect with phospholipid metabolism, suggesting that stress conditions can indirectly affect lipid metabolic flux.

CHKB-related muscular dystrophy is a human disorder associated with defects in choline/ethanolamine kinase biology, linking this enzyme family to neuromuscular pathology. Because CHKB belongs to the same kinase family that acts on choline and ethanolamine headgroups, its dysfunction illustrates how disruption of phospholipid headgroup phosphorylation can have tissue-specific consequences, particularly in muscle. Studying ethanolamine kinase activity in this context helps clarify which kinase functions are required for normal muscle membrane maintenance.

Phosphatidylethanolamine, the downstream product of the CDP-ethanolamine pathway fed by ethanolamine kinase activity, exerts metabolic control over T follicular helper cells and humoral immunity. This means that changes in ethanolamine phosphorylation could indirectly shape antibody responses through altered phosphatidylethanolamine availability. The finding positions lipid metabolic enzymes as modulators of adaptive immunity and provides a rationale for studying ethanolamine kinase activity in immunometabolism.

Hyperhomocysteinemia-aggravated hypertensive glomerular lesions involve B cell-derived anti-beta 2 glycoprotein I antibody and ferroptosis, a form of lipid peroxidation-driven cell death. Because ferroptosis depends on phospholipid composition and peroxidation, pathways that supply or remodel phosphatidylethanolamine can influence susceptibility to this injury. Ethanolamine kinase activity therefore sits upstream of lipid species that are relevant to glomerular disease mechanisms, even though direct causal evidence for the kinase itself in this model is not established in the cited work.

Ethanolamine kinase activity has been detected in purified rat brain myelin and in the cytosol of nerve endings from rat forebrain, indicating a role in neuronal membrane phospholipid metabolism. Alterations in myelin lipid composition are relevant to demyelinating and neurodegenerative conditions, so understanding this activity in neural tissue may inform studies of membrane maintenance in the nervous system. The presence of the activity in distinct brain fractions supports the idea that it serves specialized membrane lipid needs in neurons and glia.

Ethanolamine kinase activity can be measured by incubating protein fractions with ethanolamine and ATP and detecting phosphoethanolamine formation, an approach used to characterize the activity in rat liver, brain myelin, and nerve-ending cytosol. Such assays are essential for distinguishing ethanolamine kinase activity from choline kinase activity and for determining substrate specificity. They also allow comparison of activity levels across tissues and dietary conditions.

Because the reaction feeds phosphatidylethanolamine synthesis, mass spectrometry-based lipidomics can quantify phosphatidylethanolamine and related phospholipid species after genetic or nutritional perturbation. In choline-deficient rats, changes in diacylglycerols, phosphatidylcholines, and phosphatidylethanolamines were documented, showing how lipid profiling complements enzyme assays. Lipidomics is also useful for detecting peroxidation-prone phospholipid species in ferroptosis-related models.

Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway, demonstrating that gain-of-function experiments can reveal flux control. Conversely, knockout or knockdown of candidate kinases can test whether a specific gene is required for phosphoethanolamine production and downstream phosphatidylethanolamine synthesis. Combining genetic perturbation with stable-isotope tracing would allow direct assessment of pathway flux, although such tracing is not described in the cited papers.

Localization studies in rat brain fractions showed ethanolamine kinase activity in purified myelin and in nerve-ending cytosol, indicating that subcellular fractionation and imaging approaches are informative. Tagged knock-in models could extend these observations by visualizing the enzyme in intact cells. Imaging of phospholipid distribution and membrane integrity can also connect enzyme localization to function.

Researchers studying ethanolamine kinase activity-related genes often need to determine whether a candidate gene is causally involved in phosphoethanolamine production, phosphatidylethanolamine synthesis, or downstream disease phenotypes. Establishing causality typically requires precise genetic models that remove, modify, tag, or amplify the gene of interest in a controlled cellular background. EDITGENE provides the full range of CRISPR-based cell model engineering services needed to build such models and to interpret them with pathway-level readouts.

Ethanolamine kinase activity (GO:0004305) is a defined molecular function that catalyzes the ATP-dependent phosphorylation of ethanolamine to phosphoethanolamine, the committed entry step of the CDP-ethanolamine pathway for phosphatidylethanolamine synthesis. It is biochemically distinct from choline kinase in rat liver, present in brain myelin and nerve-ending fractions, and sensitive to dietary choline status, which together indicate a regulated and tissue-relevant metabolic role. Downstream phosphatidylethanolamine connects this activity to immune regulation and to disease processes such as CHKB-related muscular dystrophy and ferroptosis-associated kidney injury. For researchers, the most productive path forward is to combine precise CRISPR-based genetic models with lipidomic and biochemical readouts to determine how specific genes contribute to ethanolamine phosphorylation and to phosphatidylethanolamine-dependent phenotypes. EDITGENE supports this workflow with knockout, point-mutation, knock-in, overexpression, library-screening, and bioinformatics services tailored to ethanolamine kinase activity research.